Management

 

Dr. Michael Har-Noy

Founder, CEO and Chief Science Officer. Dr. Har-Noy is the founder and inventor of the Mirror Effect technology and serves as the CEO and Chief Science Officer of the parent Immunovative Therapies, Ltd., as well as the President of Immunovative Clinical Research, Inc, the wholly-owned Clinical Research Organization of Immunovative located to Phoenix, AZ USA. Dr. Har-Noy also serves as a consultant to the Center of Excellence for Cancer Treatment and Immunotherapy Research at the Department of Bone Marrow Transplantation and Cancer Immunotherapy at Hadassah-Hebrew University Medical Center in Jerusalem.  Early in his career, he received the National Beta Beta Beta research society first place award for undergraduate research for developing a bioreactor device which was able to maintain rat ovaries alive and cycling outside the body. As a MD-PhD student at Rush University Medical School/Loyola University he developed the first commercial scale hollow-fiver bioreactor for the production of monoclonal antibodies and other mammalian cell-derived products.  Dr. Har-Noy previously developed an autologous Th1 cell therapy for advanced cancer. While a Research Fellow at Harvard Medical School, Department of Immunology, he developed a CD4 viral-purged autologous therapy for HIV.  Dr. Har-Noy brings over 30 years’ experience in translational research in immunology and bioengineering, including pre-clinical development, manufacturing and clinical trials/regulatory affairs.

Evan Fishman, CPA.

Chief Financial Officer. Mr. Fishman joined the Company as our CFO in 2013. He is a qualified Israeli CPA as well as a qualified South African Chartered Accountant. Before joining the Company, he was the CFO and VP Operations of Minicom, a Jerusalem based hi-tech company for 12 years. Prior to that, he served as the Financial Controller of the NASDAQ listed Electric Fuel Corporation and as CFO of the Jerusalem Report.

Elena Fingerut, Ph.D.

Director of Quality Control and Manager of Research and Development and Immunomonitoring. Dr. Fingerut has been with the Company since 2006 and has been responsible for developing our GMP quality control documentation and procedures for in-coming, in-process and release of immunotherapy drug products. She has also developed and established methods for collection, shipping and testing of immunological samples from patients for evaluation of the clinical efficiency of the products. Elena has a Ph.D. from the Hebrew University, Jerusalem in Animal Science with a focus on Molecular Biology and Immunology. Elena has published several articles and was co-author in two patents in the field of vaccine development.

DGANIT COHEN

Director of Human Resources. Dganit joined Immunovative Therapies in 2016 and has over 10 years of experience in Human Resources in her previous role in Ophir Optronics Teva. She provided guidance and leadership to senior managers in international organizations through various stages of growth and stabilization. Additionally, she has considerable experience in management, training, career development and employee relations. Dganit holds a Masters Degree in Anthropology from the Hebrew University in Jerusalem. And a Bachelors Degree in Human Resource from Ben Gurion University

Tehila Sonnenfeld, Ph.D.

Director of Manufacturing and Manager of Technology Transfer. Dr. Sonnenfeld joined the Company in 2009 as a Project Manager for the development of the Company’s personalized CRCL vaccine. She was promoted in 2012 to the position of Director of manufacturing and been serving in that position since then. Dr. Sonnenfeld has a Ph.D. in Biochemistry from the Hebrew University and has published several publications in the field of proteins interactions.

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more